OTCQX:MRVFF - Post by User
Comment by
daydream1on Apr 17, 2012 11:12am
454 Views
Post# 19802723
RE: New Investor Presentation Posted
RE: New Investor Presentation Posted While we wait for the FDA hammer to come down, lets do some basic arithmetic. Nuvo's Q1 reported a cash position of $14,728,000 or about $15 million. Pennsaid sale being exponentially growing we can safely assume that at the very lest NRI in Q2 will still have $15 million (if not more) in cash. If Pliaglis pass the FDA. NRI gets $8 million in milestone payment since Pliaglis is already accepted in South America (Argentina).
This gives a $23 million cash value for NRI or 0.042/shares. With a conservative multiple of 5 NRI shares value would sit at 0.21/share.
If the FDA turn down or delay the acceptance of Pliaglis then we’re back at about 0.06/share for a little longer.
The way I see it, under very conservative assumptions, there is a 50/50 percent chance of making about 8 cents/share from the current share price. It a gamble but the odd are much better than that your average casino can offer. I am keeping my position.
Goodluck
D